The Use of NeuroAiD (MLC601) in Postischemic Stroke Patients

The Use of NeuroAiD (MLC601) in Postischemic Stroke Patients

Aim. We aimed to assess the efficacy of MLC601 on functional recovery in patients given MLC601 after an ischemic stroke. Methods. This is a retrospective cohort study comparing poststroke patients given open-label MLC601 (; 9 female) for three months and matching patients who did not receive MLC601...

Full description

Bibliographic Details
Main Authors:	Jose C. Navarro, Mark C. Molina, Alejandro C. Baroque II, Johnny K. Lokin
Format:	Article
Language:	English
Published:	Hindawi Limited 2012-01-01
Series:	Rehabilitation Research and Practice
Online Access:	http://dx.doi.org/10.1155/2012/506387

Similar Items

Safety and Use of MLC601/MLC901 (NeuroAiD<sup>TM</sup>) in Primary Intracerebral Hemorrhage: A Cohort Study from the NeuroAiD Safe Treatment Registry
by: Ramesh Kumar, et al.
Published: (2020-07-01)

Clinical Outcomes of MLC601 (NeuroAiD<sup>TM</sup>) in Traumatic Brain Injury: A Pilot Study
by: Asra Al Fauzi, et al.
Published: (2020-01-01)

NeuroAid II (MLC901) in Haemorrhagic Stroke
by: Chai-Hoon Nowel Tan, et al.
Published: (2020-12-01)

NeuroAid II (MLC901) and polypharmacy in stroke and the risk of hepatotoxicity: a case report
by: Abdul Rashid, A.M, et al.
Published: (2021)

NeuroAid II (MLC901) and polypharmacy in stroke and the risk of hepatotoxicity: a case report
by: Baharin, J, et al.
Published: (2021)

Systematic Review and Meta-Analysis of the Efficacy of MLC901 (NeuroAiD II) for Acute Ischemic Brain Injury in Animal Models
by: I. G. M. Aswin R. Ranuh MD, et al.
Published: (2021-08-01)

Contribution of CNS cells in NeuroAIDS
by: Ashish Swarup Verma, et al.
Published: (2010-01-01)

MLC601 in vascular dementia: an efficacy and safety pilot study
by: Pakdaman H, et al.
Published: (2017-10-01)

Simian Immunodeficiency Virus: A Model for NeuroAIDS
by: Howard S. Fox, et al.
Published: (1997-01-01)

Proceedings of the ISEV symposium on “HIV, NeuroAIDS, drug abuse & EVs”
by: Guoku Hu, et al.
Published: (2017-12-01)

Safety and Efficacy of MLC601 in Iranian Patients after Stroke: A Double-Blind, Placebo-Controlled Clinical Trial
by: A. A. Harandi, et al.
Published: (2011-01-01)

NIMH funding opportunities for NeuroAIDS therapeutics development research
by: Kopnisky Kathy, et al.
Published: (2006-12-01)

Global Perspective of Novel Therapeutic Strategies for the Management of NeuroAIDS
by: Kumar Swatantra, et al.
Published: (2018-05-01)

Nose to brain delivery of antiretroviral drugs in the treatment of neuroAIDS
by: Anupam Sarma, et al.
Published: (2020-12-01)

Minocycline inhibition of monocyte activation correlates with neuronal protection in SIV neuroAIDS.
by: Jennifer H Campbell, et al.
Published: (2011-04-01)

HIV-Tat regulates macrophage gene expression in the context of neuroAIDS.
by: Loreto Carvallo, et al.
Published: (2017-01-01)

Sustained-release nanoART formulation for the treatment of neuroAIDS
by: Jayant RD, et al.
Published: (2015-02-01)

Advances in SIV/SHIV Non-Human Primate Models of NeuroAIDS
by: Sonia Moretti, et al.
Published: (2021-08-01)

Common gene-network signature of different neurological disorders and their potential implications to neuroAIDS.
by: Vidya Sagar, et al.
Published: (2017-01-01)

Temporal/compartmental changes in viral RNA and neuronal injury in a primate model of NeuroAIDS.
by: R Gilberto González, et al.
Published: (2018-01-01)

Effectiveness and Safety of MLC601 in the Treatment of Mild to Moderate Alzheimer's Disease: A Multicenter, Randomized Controlled Trial
by: Hossein Pakdaman, et al.
Published: (2015-03-01)

A SIV molecular clone that targets the CNS and induces neuroAIDS in rhesus macaques.
by: Kenta Matsuda, et al.
Published: (2017-08-01)

Efficacy and Safety of MLC601 in Patients with Mild to Moderate Alzheimer Disease: An Extension 4-Year Follow-Up Study
by: Hossein Pakdaman, et al.
Published: (2018-04-01)

Interactive Effects of Cocaine on HIV Infection: Implication in HIV-Associated Neurocognitive Disorder and NeuroAIDS
by: Santosh eDahal, et al.
Published: (2015-09-01)

HIV-tat protein mediation of neuroAIDS central nervous system pathology and behavioral deficits
Published: ()

Clathrin-nanoparticles deliver BDNF to hippocampus and enhance neurogenesis, synaptogenesis and cognition in HIV/neuroAIDS mouse model
by: Adam, C.W, et al.
Published: (2022)

Efficacy and Safety of MLC601 in the Treatment of Mild Cognitive Impairment: A Pilot, Randomized, Double-Blind, Placebo-Controlled Study
by: Hossein Pakdaman, et al.
Published: (2017-05-01)

Boosting the Brain Delivery of Atazanavir through Nanostructured Lipid Carrier-Based Approach for Mitigating NeuroAIDS
by: Saif Ahmad Khan, et al.
Published: (2020-11-01)

Proton magnetic resonance spectroscopy reveals neuroprotection by oral minocycline in a nonhuman primate model of accelerated NeuroAIDS.
by: Eva-Maria Ratai, et al.
Published: (2010-05-01)

The National NeuroAIDS Tissue Consortium brain gene array: two types of HIV-associated neurocognitive impairment.
by: Benjamin B Gelman, et al.
Published: (2012-01-01)

Overexpression and activation of colony-stimulating factor 1 receptor in the SIV/macaque model of HIV infection and neuroAIDS
by: Woong-Ki Kim, et al.
Published: (2018-05-01)

The Effect of Hyperbaric Oxygen on Brain Macrophage after the Postischemic Stroke in Rats
by: Chang, Hsien-Feng, et al.
Published: (2002)

The Effect of Hyperbaric Oxygen on Neuron Survival after the Postischemic Stroke in Rats
by: Jiang , Shu-Hai, et al.
Published: (2002)

A prospective longitudinal <it>in vivo </it><sup>1</sup>H MR spectroscopy study of the SIV/macaque model of neuroAIDS
by: Halpern Elkan, et al.
Published: (2004-03-01)

Transthyretin expression in the postischemic brain.
by: Daniela Talhada, et al.
Published: (2019-01-01)

Monocytes-derived macrophages mediated stable expression of human brain-derived neurotrophic factor, a novel therapeutic strategy for neuroAIDS.
by: Jing Tong, et al.
Published: (2014-01-01)

Lentiviral vector-mediated stable expression of sTNFR-Fc in human macrophage and neuronal cells as a potential therapy for neuroAIDS
by: Maggirwar Sanjay B, et al.
Published: (2011-05-01)

Effects of morphine and NeuroAid on the expression levels of GluN2A and GluN3A in the hippocampus and striatum of rats
by: Katayoun Heshmatzad, et al.
Published: (2021-04-01)

MicroRNAs in Postischemic Vascular Repair
by: Andrea Caporali, et al.
Published: (2012-01-01)

Correction: Transthyretin expression in the postischemic brain.
by: Daniela Talhada, et al.
Published: (2020-01-01)